Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Mounjaro, FDA and Zepbound
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
FDA keeps Mounjaro off shortage list after reevaluation
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from the federal drug shortage list
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the first medication for certain patients with the condition.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to do so in the future.
FDA declares shortage over for popular weight-loss, diabetes drugs
The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic versions of Mounjaro or Zepbound.
FDA: No more need for compounded versions of Mounjaro, Zepbound
The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the production of compounded versions of the drugs, Bloomberg reported Dec. 19.
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
10h
FDA approves Zepbound for obstructive sleep apnea
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
2d
on MSN
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
3d
on MSN
FDA Says Shortage of Eli Lilly’s Zepbound Is Over, but Gives Compounders a Grace Period
The Food and Drug Administration said Thursday that the longstanding shortage of Eli Lilly’s weight-loss drug Zepbound and ...
2d
Nestle's GLP-1 'shot,' the FDA's Zepbound ruling, and Ozempic lures people to the doctor: Pharma news roundup
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback